A 63-year-old man whose prostate had swollen to 297 milliliters, roughly three and a half times the size at which a common minimally invasive therapy is normally offered, has now spent a year free of his catheter and largely free of the urinary symptoms that had eroded his daily life. His treatment was Rezūm water vapor thermal therapy, a procedure that injects bursts of steam into the prostate to destroy excess tissue, and it was performed despite the fact that the therapy is typically recommended only for prostates smaller than 80 milliliters. The case, reported in the African Journal of Urology, is being described as one of the largest prostate volumes ever treated with this technique.
The details matter because they show how a technology designed for small glands was stretched, with deliberate adjustments, to an extreme size. The procedure required 21 steam injections, 11 on the right side and 10 on the left, far more than the handful used in standard cases. The surgeon kept a Foley catheter in place for 28 days rather than the usual 7 to 9 days, anticipating that a gland of that size would swell dramatically after treatment. Saline irrigation volume was 420 milliliters, the scope time was just 6 minutes, and bleeding was scored as minimal, with negligible estimated blood loss.
Rezūm works by convective steam energy. Water vapor heated to high temperature is delivered through needles into targeted zones of the prostate, where the thermal energy kills cells in a controlled way. The dead tissue shrinks over the following weeks and months, opening the channel through which urine flows. Randomized trials have shown sustained improvements in symptoms and quality of life, but those studies overwhelmingly enrolled men with prostate volumes of 80 milliliters or less, leaving outcomes in very large glands poorly characterized.
The patient in this report had a ten-year history of progressive lower urinary tract symptoms attributable to benign prostatic hyperplasia, the noncancerous enlargement that affects a large share of aging men. He had already tried iTind therapy in 2016, which briefly reduced his nighttime urination and improved urinary frequency, but his symptoms returned. By 2023 he was experiencing severe daytime frequency, urgency with occasional urge incontinence, hesitancy, a weak stream, intermittency, and painful urination. His International Prostate Symptom Score, a standard questionnaire, stood at 22 out of a possible 35, with a quality-of-life score of 4. Twice-daily tamsulosin offered limited relief.
In June 2024 he arrived with recurrent acute urinary retention and needed an indwelling Foley catheter. Cystoscopy showed enlargement on both sides of the prostate without an obstructing median lobe, the anatomical feature that often complicates therapy. He wanted strongly to preserve sexual function and was worried about the risks of holmium laser enucleation or simple prostatectomy, the established operations for very large glands. After counseling that included an honest discussion of the limited evidence for Rezūm at his gland size, he chose the steam therapy. Transrectal ultrasound in July 2024 confirmed the prostate measured 297 milliliters. His only other medical issue was mild asthma.
The one-year numbers are striking. His symptom score fell from 22 to 4, and his quality-of-life score improved from 4 to 2. Peak urine flow rate, measured as Qmax, reached 9.4 milliliters per second, with a pre-void volume of 374 milliliters and a post-void residual of 57 milliliters, meaning his bladder was emptying well. His prostate-specific antigen, a blood marker that can rise with prostate tissue volume, dropped from 5.1 to 1.8 nanograms per milliliter, a change the authors attribute to the loss of treated tissue, though they caution that PSA is an indirect marker and the baseline may have been inflated by the urinary retention and catheterization he experienced before treatment.
Sexual function held steady. One month after catheter removal his International Index of Erectile Function score was 38, and his Male Sexual Health Questionnaire ejaculatory dysfunction function score was 8 with a bother score of 2. At the one-month mark his symptom score had already improved to 14. He reported high satisfaction with both urinary and sexual outcomes and declined any further intervention.
The authors are careful about what this single case can and cannot show. Rezūm is approved for prostates under 80 milliliters, and using it at nearly 300 milliliters is off-label. Emerging evidence supports its use in glands between 80 and 120 milliliters, and prior reports describe successful treatment at sizes up to roughly 180 to 200 milliliters, including a case at 186 milliliters and studies of men with median volumes around 100 milliliters. This case extends that experience to nearly 300 milliliters, but a single patient cannot establish safety or efficacy at a population level, and the authors explicitly state the findings should be considered hypothesis generating rather than confirmatory.
There are also honest caveats about the results themselves. A one-year peak flow rate of 9.4 milliliters per second falls within a range that can still be seen with persistent bladder outlet obstruction, so the improvement, while substantial relative to his baseline, does not prove the obstruction is fully resolved. Post-treatment prostate volume was not measured by imaging, which limits any assessment of how much tissue was actually ablated. Long-term durability in this extreme size range is unknown, and continued follow-up will be needed to determine whether he eventually requires another procedure.
What makes the case worth attention is the combination of an extreme anatomical challenge, a deliberately adapted technique, and a preserved quality of life that the patient himself judged worth keeping. For men with very large prostates who want to avoid more invasive surgery, it offers a data point rather than a prescription. The authors call for dedicated prospective studies with comparator groups to formally evaluate Rezūm in this subgroup and to define which patients, if any, should be offered it routinely. Until then, the case stands as a carefully documented proof of possibility, not a change in practice.
Subject of Research: A case report of Rezūm water vapor thermal therapy in a patient with an extremely large 297 mL prostate
Article Title: Successful Rezūm water vapor thermal therapy in a patient with extremely large prostate volume: a case report
Article References: Fields, E., Aldoukhi, M., Bitar, M., Pompili, D., Alamri, N., & Elterman, D. (2026). Successful Rezūm water vapor thermal therapy in a patient with extremely large prostate volume: a case report. African Journal of Urology, 32(1), Article 81. https://doi.org/10.1186/s12301-026-00630-1
Image Credits: AI Generated
DOI: 10.1186/s12301-026-00630-1
Keywords: Rezūm, water vapor therapy, benign prostatic hyperplasia, prostate volume, lower urinary tract symptoms, minimally invasive surgery, case report, PSA reduction, uroflowmetry, off-label use, sexual function preservation, African Journal of Urology
News Source: Ophelia Keating. (November 6, 2026). Steam Therapy Shrinks a 297 mL Prostate When Surgery Felt Too Risky. Scienmag.



